Novo Nordisk A/S

The global oral proteins and peptides market is projected to reach USD 20.36 billion by 2029, driven by increasing demand for oral peptides in treating chronic diseases, R&D investments, and advancements in drug delivery technologies. The US dominates the market, supported by a strong biopharmaceutical sector and presence of key players like Novo Nordisk and Pfizer. Semaglutide leads in molecule segments, used for managing type-2 diabetes and obesity.

New data from Viking Therapeutics and AstraZeneca highlights competitive weight-loss pill development, with potential market value reaching $130 billion by 2030. Viking's pill showed a 6.8% weight loss in early trials, while AstraZeneca's drug demonstrated a 5.8% reduction in diabetics. Other pharmaceutical giants like Eli Lilly and Novo Nordisk are also in the race, focusing on convenience and reduced side effects. The industry faces challenges including high R&D costs, regulatory hurdles, and ethical debates over drug pricing and accessibility.

Cytoki Pharma announces first patient dosed in Phase 2 study of CK-0045, evaluating efficacy, safety, and tolerability in obesity and type 2 diabetes.

Chapters cover methodology, executive summary, market variables, segmentation by disease, molecule, biological target, mechanism, and region, and competitive landscape.

The global biotechnology market, valued at USD 1.37 trillion in 2022, is projected to grow at a CAGR of 13.8% driven by technological advancements, increased R&D, and demand for innovative applications in healthcare and agriculture. Key technologies include 3D bioprinting, genomic analysis, fermentation, nanotechnology, and bioinformatics. Major players include AstraZeneca, Gilead Sciences, Novo Nordisk, Abbott Laboratories, Amgen, Thermo Fisher Scientific, Merck KgaA, Johnson & Johnson, Novartis, Hoffmann-La Roche, Pfizer, and Moderna. Challenges include high costs, regulatory constraints, and ethical considerations.

SMART trial results presented at Kidney Week 2024 show semaglutide reduces UACR by -52.1% in nondiabetic CKD patients, with sustained effects post-treatment. No significant Cr-eGFR difference observed, but weight and waist circumference reduced. Study explores semaglutide's potential in kidney and cardiovascular care.

The weight management market is rapidly expanding, with SNS Insider projecting a 43.73% annual growth rate through 2032. Major pharmaceutical companies like Novo Nordisk, Eli Lilly, and Roche are entering the market, anticipating a 15-fold increase in obesity drug sales over five years. PlantX Life Inc. has partnered with LIV3 to launch SugarShield, a plant-based weight loss supplement targeting the $5.24bn market. Novo Nordisk's SOUL trial showed oral semaglutide reduced MACE by 14% in type 2 diabetes patients, while Eli Lilly is suing vendors for selling copycat tirzepatide. Viking Therapeutics and Roche are also advancing in obesity drug development.

PlantX Life Inc. announces joint venture with LIV3 to launch SugarShield supplement, targeting the $5.24 billion weight loss management market. The supplement aims to boost energy, curb cravings, and simplify weight management without restrictive diets, leveraging PlantX's expertise in branding and digital platforms.

Catumaxomab, now branded as Korjuny, received a positive opinion from the EMA's CHMP for treating malignant ascites, marking its return after a decade off the market. Korjuny, a bispecific and trifunctional antibody, engages Epcam on cancer cells and CD3 on T cells, recruiting immune cells to destroy tumor cells. The EMA approval is limited to malignant ascites, but ongoing trials aim to expand its use, including a global phase III trial in advanced gastric cancer.

Veru Inc. will present at ObesityWeek on November 5, 2024, discussing enobosarm's potential to optimize weight loss. The Phase 2b clinical trial evaluates enobosarm's safety and efficacy in preserving muscle and augmenting fat loss in sarcopenic obese patients. Topline results are expected in January 2025, with extension study results in Q2 2025.